Table 2.
Different NHP/SIV models used in cure research.a
| Non-human primate species | SIV strains | Acute VLs | Chronic VLs | Spontaneous elite control? | Rapid progression (frequency of RP) | Control with conventional ART | Use of NNRTI | Chronic immune activation |
|---|---|---|---|---|---|---|---|---|
| Indian rhesus macaque | SIVmac251/239 | 107–109 | 104–107 | Yes (for specific MHC types) | 30–40% | Requires complex combinations | No | Yes |
| SIVsmm | 107–108 | 102–105 | Yes (for specific Trim genotypes) | No | Yes | No | Yes | |
| SIVagmSab | 106–109 | <3–100 | 100% | No | No data | No | No | |
| RT-SHIV | 105–108 | 103–106 | Yes (for specific MHC types) | No | Requires complex combinations | Yes | Yes | |
| Chinese rhesus macaque | SIVmac239 | 105–107 | 10–105 | Yes (~33%) | No | Yes | No | Yes |
| Pigtailed macaque | SIVmac251/239 | 105–109 | 103–106 | Rare | 30–40% | Requires complex combinations | No | Yes |
| SIVsmm | 105–109 | 104–107 | No | >75% | Requires complex combinations | No | Yes | |
| SIVagmSab | 107–109 | 104–106 | No | 30–40% | No data | No | Yes | |
| RT-SHIV | 104–107 | 103–105 | Rare | >75% | Yes | Yes | Yes | |
| Cynomolgus macaque | SIVmac251/239 | 106–108 | 102–105 | Yes (~30%) | No | Yes | No | No data |
aHaase (56), Lackner and Veazey (57), Demberg et al. (58), Horiike et al. (59), Pandrea et al. (60), Ma et al. (61), Uberla et al. (62), North et al. (12), North et al. (63), Kauffman et al. (64), Monceaux et al. (65), Ling et al. (66), Ling et al. (67), Klatt et al. (68), Dinoso et al. (27), Canary et al. (69), Hirsch et al. (70), Mandell et al. (71), Kristoff et al. (72), Ambrose et al. (73), Shao et al. (74), Kearney et al. (75), Kline et al. (13), Benlhassan-Chahour et al. (76), Mannioui et al. (77), Sellier et al. (78), Reimann et al. (79), and Budde et al. (80).